Avenue Therapeutics, Inc.
ATXI
$0.773
-$0.1725-18.24%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -25.97% | -11.20% | -14.49% | -21.83% | 156.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -27.72% | -28.20% | 1.79% | 80.77% | 223.73% |
| Operating Income | 27.72% | 28.20% | -1.79% | -80.77% | -223.73% |
| Income Before Tax | 10.03% | 49.64% | 13.29% | -191.09% | -109.94% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 10.03% | 49.64% | 13.29% | -191.09% | -109.94% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -62.59% | -57.14% | -53.85% | 117.65% | -- |
| Net Income | 9.33% | 49.56% | 12.71% | -192.15% | -107.18% |
| EBIT | 27.72% | 28.20% | -1.79% | -80.77% | -223.73% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 82.93% | 91.08% | 70.02% | 36.20% | 54.26% |
| Normalized Basic EPS | 92.22% | 98.26% | 74.86% | 36.38% | 54.69% |
| EPS Diluted | 82.94% | 91.08% | 70.03% | 36.22% | 54.23% |
| Normalized Diluted EPS | 92.22% | 98.26% | 74.86% | 36.38% | 54.69% |
| Average Basic Shares Outstanding | 932.40% | 707.30% | 511.45% | 384.55% | 367.07% |
| Average Diluted Shares Outstanding | 932.40% | 707.30% | 511.45% | 384.55% | 367.07% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
